• Ph.D. from National Taiwan University College of Medicine, with over 30 years of dedicated research in immunology and microbial therapy.

• Invented the patented strain LP33, pioneering indigenous probiotic R&D in Taiwan.
• Founder of Gaohe Hospital,the integrated medical model of "Traditional Chinese Medicine Syndrome Differentiation + Western Evidence-Based Medicine" in Taiwan.
• Under the guidance of immunology authority Professor Hsieh Kuei-Hsiung, invented the "DNA Vaccine Gene Therapy for Respiratory Allergies," with research published in the top-tier international scientific journal Nature Medicine—a first for Taiwan.
• Mackay Memorial Hospital Best Resident Physician of 1993 and 1994
• Taiwan Pediatric Association Research Award
• National Taiwan University College of Medicine Research Award
• Taiwan Pediatric Association Nestal Research Award
• Wang Min-Ning Memorial Fund Research Award
• Taiwan Pediatric Association The New Categorical Award

As Chairman, he oversees the group's strategic direction, ensuring all business operations revolve around the core philosophy of "Do No Harm (Medicine Without Harm)." He leads BioRay's deep partnerships with medical institutions such as Gaohe Hospital and Chi Mei Hospital, driving the implementation of end-to-end health services from "testing to treatment to wellness." He also spearheads international collaborations (such as the Indonesia BGI licensing), bringing Taiwan's technology to Southeast Asian markets and laying the groundwork for global expansion during the IPO stage.

• Ph.D. from National Sun Yat-sen University Institute of Biotechnology, specializing in microbial fermentation technology, natural active ingredient extraction, and laboratory quality control.
• Led the R&D of BioRay's 13 patented probiotic strains (including anti-allergy BRAP-01, gut health BR022, etc.), securing 42 international patents.
• Led BioRay's laboratory to achieve TAF ISO/IEC 17025 and LDTS (Precision Medicine Molecular Testing Laboratory) certifications, establishing a comprehensive testing data quality control system.
• Led the Pingtung facility to achieve ISO 22000 and HACCP international certifications, standardizing health food production processes.
• Honored as "2023 Asia Biotech Expo R&D Leader of the Year."

As General Manager, she oversees the group's R&D, production, and testing operations, leading the team to breakthroughs in core technologies such as "mulberry leaf-probiotic symbiotic fermentation" and "anti-blue-light Cordyceps xanthophyll." As Laboratory Director, she established the laboratory's "end-to-end quality control standards," ensuring that cancer NGS testing and immune function analysis data are 100% compliant with Taiwan FDA requirements. She drives the alignment of testing technologies with clinical needs (such as providing supporting tests for CIK cell therapy), while optimizing production costs to make patented products more accessible—fueling business growth and brand trust expansion during the IPO stage.